Grow Opportunity

News Export International Production
Isracann Bioscience facilitates cannabis genetics shipment to Israel

September 14, 2022  By Haley Nagasaki

(Globe Newswire) Vancouver — Isracann Biosciences Inc., a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor, is pleased to announce it has facilitated its first shipment of cannabis strains to Israel.

The agreement for genetics is directly between United Greeneries Ltd, a licensed Canadian producer of high calibre craft cannabis, and Intelicanna, a licensed Israeli medical cannabis grower and brand. Three initial premium strains are included in the agreement, with the provision for additional strains.

Under a revenue sharing agreement, United Greeneries shall be responsible for cultivation and genetics support, with in-country support provided by Isracann.

“Israel is the largest importer of Canadian cannabis in the world. The primary reason for this is that the domestic market lacks the high THC strains that are available outside the country. I am excited that Isracann, through our agreement with United Greeneries, was able to arrange for this shipment of genetics to Intelicanna and we look forward to expanding this offering. United Greeneries Ltd. continues to deliver some of the highest potency Sativa and Indica strains to the domestic Canadian market and look to support Intelicanna to do the same in Israel.” — CEO Phil Floucault


Since 2021, Intelicanna has been growing and selling medicinal cannabis for the Israeli market under the Intelicanna brand. Their HaSharon facility is one of the most advanced in Israel, and includes 5,500 m2 of hybrid greenhouse with full light, shade, and climate controls.

“This first shipment is due to arrive in Israel in the near term. We have been working with Intelicanna to have everything ready to receive the clones and expedite the process of scaling up to full production. In a short timeline, Canadian quality cannabis will be grown in Israel.” — Phil Floucault

Print this page


Stories continue below